← Leaderboards
Bruce R Conklin
J. David Gladstone Institutes
$31,972,475
Attributed
$48,602,749
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,602,749 · 18
By mechanism
U01$22,127,023 · 4
R01$21,728,538 · 9
RF1$2,365,559 · 1
P01$2,333,879 · 3
R03$47,750 · 1
Top collaborators
- Benoit Gaetan Bruneau15 shared
- Deepak Srivastava15 shared
- Shinya Yamanaka15 shared
- Laurie A Boyer6 shared
- Katherine Snowden Pollard6 shared
- Kevin E Healy4 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInduced Pluripotent Stem CellCardiacBaseGenesComplexMutationGenomeGeneticHeartCell LineEngineeringFutureGenomicsResearch PersonnelMolecularGene ExpressionBiologyMutantProteinsCardiac MyocytesTissuesTechnologyEmbryonic Stem Cell
Grant awards (81)
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches$694,575
R01 · FY2025 · AG · contact PI
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches$708,750
R01 · FY2024 · AG · contact PI
Core C: Genome Engineering Core$283,535
P01 · FY2023 · HL · contact PI
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing$720,836
U01 · FY2022 · ES · contact PI
Core C: Genome Engineering Core$283,535
P01 · FY2022 · HL · contact PI
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches$239,309
RF1 · FY2022 · AG · contact PI
JAX-Gladstone, SCGE Disease Models Studies Supplement$200,000
U01 · FY2022 · ES · contact PI
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches$2,126,250
RF1 · FY2021 · AG · contact PI
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing$720,836
U01 · FY2021 · ES · contact PI
Therapeutic genome editing to treat Best disease$412,056
R01 · FY2021 · EY · contact PI
Core C: Genome Engineering Core$283,535
P01 · FY2021 · HL · contact PI
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs$524,517
R01 · FY2020 · HL · contact PI
Therapeutic genome editing to treat Best disease$472,500
R01 · FY2020 · EY · contact PI
Therapeutic genome editing to treat Best disease$424,800
R01 · FY2020 · EY · contact PI
Core C: Genome Engineering Core$283,535
P01 · FY2020 · HL · contact PI
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs$472,000
R01 · FY2019 · HL · contact PI
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy$456,506
R01 · FY2019 · HL · contact PI
Therapeutic genome editing to treat Best disease$424,800
R01 · FY2019 · EY · contact PI
Core C: Genome Engineering Core$286,713
P01 · FY2019 · HL · contact PI
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs$44,079
R01 · FY2019 · HL · contact PI
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs$472,000
R01 · FY2018 · HL · contact PI
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy$456,506
R01 · FY2018 · HL · contact PI
Therapeutic genome editing to treat Best disease$424,800
R01 · FY2018 · EY · contact PI
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs$472,000
R01 · FY2017 · HL · contact PI
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy$456,506
R01 · FY2017 · HL · contact PI
Therapeutic genome editing to treat Best disease$424,800
R01 · FY2017 · EY · contact PI
Cell Production Core$171,459
P01 · FY2017 · HL · contact PI
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy$478,831
R01 · FY2016 · HL · contact PI
Cell Production Core$172,885
P01 · FY2016 · HL · contact PI
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,316,397
U01 · FY2015 · HL
Cell Production Core$201,159
P01 · FY2015 · HL · contact PI
The Epigenetic Landscape of Heart Development$1,925,664
U01 · FY2014 · HL
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,370,677
U01 · FY2014 · HL
Disease Specific Cardiac Tissue Models$605,351
R01 · FY2014 · HL
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)$202,410
U01 · FY2014 · GM · contact PI
Cell Production Core$185,691
P01 · FY2014 · HL · contact PI
The Epigenetic Landscape of Heart Development$1,871,454
U01 · FY2013 · HL
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,331,513
U01 · FY2013 · HL
Disease Specific Cardiac Tissue Models$577,388
R01 · FY2013 · HL
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)$215,095
U01 · FY2013 · GM · contact PI
Cell Production Core$181,832
P01 · FY2013 · HL · contact PI
The Epigenetic Landscape of Heart Development$1,966,621
U01 · FY2012 · HL
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,326,006
U01 · FY2012 · HL
Disease Specific Cardiac Tissue Models$616,515
R01 · FY2012 · HL
Tissue Engineering with a Modular RASSL Toolbox$480,338
R01 · FY2012 · HL · contact PI
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)$206,399
U01 · FY2012 · GM · contact PI
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$49,054
U01 · FY2012 · HL
The Epigenetic Landscape of Heart Development$1,987,290
U01 · FY2011 · HL
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,326,006
U01 · FY2011 · HL
Tissue Engineering with a Modular RASSL Toolbox$642,839
R01 · FY2011 · HL · contact PI
Disease Specific Cardiac Tissue Models$627,859
R01 · FY2011 · HL
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)$228,566
U01 · FY2011 · GM · contact PI
The Epigenetic Landscape of Heart Development$1,948,483
U01 · FY2010 · HL
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,312,613
U01 · FY2010 · HL
Tissue Engineering with a Modular RASSL Toolbox$649,334
R01 · FY2010 · HL · contact PI
GenMAPP-CS, a dynamic resource pathway analysis$397,091
R01 · FY2010 · GM · contact PI
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)$238,628
U01 · FY2010 · GM · contact PI
Induced Pluripotent Stem Cells in the Understanding and Treatment of Heart Diseas$1,339,401
U01 · FY2009 · HL
Tissue Engineering with a Modular RASSL Toolbox$645,952
R01 · FY2009 · HL · contact PI
GenMAPP-CS, a dynamic resource pathway analysis$401,102
R01 · FY2009 · GM · contact PI
GenMAPP-CS, a dynamic resource pathway analysis$370,985
R01 · FY2009 · GM · contact PI
The Epigenetic Landscape of Heart Development$323,074
U01 · FY2009 · HL
Induced pluripotent stem cells in the understanding and treatment of heart diseas$47,750
R03 · FY2009 · HL
Tissue Engineering with a Modular RASSL Toolbox$26,243
R01 · FY2009 · HL · contact PI
Tissue Engineering with a Modular RASSL Toolbox$629,826
R01 · FY2008 · HL · contact PI
GenMAPP-CS, a dynamic resource pathway analysis$401,139
R01 · FY2008 · GM · contact PI
Tissue engineering with a complete RASSL toolbox$614,684
R01 · FY2007 · HL · contact PI
GenMAPP-CS, a dynamic resource pathway analysis$421,697
R01 · FY2007 · GM · contact PI
Tissue engineering with a complete RASSL toolbox$614,896
R01 · FY2006 · HL · contact PI
GenMAPP: A tool for pathway analysis of genomic data$436,725
R01 · FY2006 · HG · contact PI
Tissue engineering with a complete RASSL toolbox$566,136
R01 · FY2005 · HL
GenMAPP: A tool for pathway analysis of genomic data$435,174
R01 · FY2005 · HG
Tissue engineering with a complete RASSL toolbox$466,456
R01 · FY2004 · HL
GenMAPP: A tool for pathway analysis of genomic data$422,664
R01 · FY2004 · HG
Tissue engineering with a complete RASSL toolbox$452,870
R01 · FY2003 · HL
GI SIGNALING AND CARDIOMYOPATHY$409,635
R01 · FY2002 · HL
COLLABORATIVE R01--ROLES OF G PROTEINS IN CARDIOMYOPATHY$403,605
R01 · FY2002 · HL
COLLABORATIVE R01--ROLES OF G PROTEINS IN CARDIOMYOPATHY$403,605
R01 · FY2001 · HL
GI SIGNALING AND CARDIOMYOPATHY$398,032
R01 · FY2001 · HL
COLLABORATIVE R01--ROLES OF G PROTEINS IN CARDIOMYOPATHY$403,605
R01 · FY2000 · HL
GI SIGNALING AND CARDIOMYOPATHY$386,766
R01 · FY2000 · HL